Miller, PhD, GTx Director of Medicinal Chemistry since 2003, is the Harriet S. Miller has been inducted into the American Chemical Society’s Medicinal Chemistry Hall of Fame and was the recipient of the 2008 Division of Medicinal Chemistry award. Miller moved to the University of Tennessee at Memphis as the Van Vleet Professor of Medicinal Chemistry, and in 2001 was appointed Associate Dean for Research and Graduate Programs in the College of Pharmacy. Merck and GTx are conducting several Phase I and Phase II clinical trials evaluating multiple SARM product candidates, including Ostarine™ (also designated as MK-2866) for sarcopenia. GTx’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risks that (i) GTx and its collaboration partners will not be able to commercialize their product candidates if clinical trials do not demonstrate safety and efficacy in humans; (ii) GTx may not able to obtain required regulatory approvals to commercialize product candidates; (iii) clinical trials being conducted by GTx and its collaboration partners may not be completed on schedule, or at all, or may otherwise be suspended or terminated; and (iv) GTx could utilize its available cash resources sooner than it currently expects and may be unable to raise capital when needed, which would force GTx to delay, reduce or eliminate its product development programs or commercialization efforts. GTx expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. read more
Technorati Tags: gtx, medicinal, chemistry, miller, statements, clinical, weight loss news
This entry was posted
on Friday, January 30th, 2009 at 7:47 pm and is filed under Weight Loss News.
You can follow any responses to this entry through the RSS 2.0 feed.
Responses are currently closed, but you can trackback from your own site.
Loading ...
